Cargando…

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials

PURPOSE: Epidermal growth factor receptor inhibitors such as panitumumab are associated with characteristic skin toxicities. We summarise data from three panitumumab clinical trials to investigate the potential impact of skin toxicity on quality of life (QoL) in patients with metastatic colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koukakis, Reija, Gatta, Francesca, Hechmati, Guy, Siena, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010834/ https://www.ncbi.nlm.nih.gov/pubmed/27083443 http://dx.doi.org/10.1007/s11136-016-1288-4

Ejemplares similares

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
por: Siena, Salvatore, et al.
Publicado: (2016)

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
por: Taieb, Julien, et al.
Publicado: (2017)

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
por: Peeters, Marc, et al.
Publicado: (2018)

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
por: Köhne, Claus-Henning, et al.
Publicado: (2019)

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
por: Modest, Dominik Paul, et al.
Publicado: (2019)

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC
por: Hebart, Holger, et al.
Publicado: (2019)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
por: Boeckx, N., et al.
Publicado: (2017)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan
por: Kashiwa, Munenobu, et al.
Publicado: (2021)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
por: Karthaus, Meinolf, et al.
Publicado: (2016)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
por: Siu, Ho Wai Derrick, et al.
Publicado: (2021)

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
por: Kato, Takeshi, et al.
Publicado: (2021)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
por: Aparicio, Jorge, et al.
Publicado: (2022)

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
por: Kim, Tae Won, et al.
Publicado: (2016)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Napolitano, Stefania, et al.
Publicado: (2023)

The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results
por: Terazawa, Tetsuji, et al.
Publicado: (2022)

An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer
por: Poulin-Costello, Melanie, et al.
Publicado: (2013)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
por: Han van Krieken, J., et al.
Publicado: (2017)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7o8govjue12n91vskarhdrv3f2